Testing vicadrostat plus empagliflozin for diabetes, high blood pressure, and heart disease
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests a new pill called vicadrostat taken with another medicine (empagliflozin) to see if it helps people with type 2 diabetes, high blood pressure, and heart disease. It may reduce the risk of heart problems, but you must not have had heart failure or use certain other heart medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have high blood pressure and take medicine for it
- You have type 2 diabetes and take medicine for it
- You have a history of heart disease and take medicine for it
- You have at least one extra risk factor for developing heart failure (like poor kidney function or older age)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a new medicine (vicadrostat) works differently than an older one (spironolactone) in people with heart failure or heart disease and reduced kidney function. It aims to understand how they affect proteins in the blood and kidney blood flow.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
This study looks at how well a medication called Enavogliflozin works for people with type 2 diabetes who also have high blood pressure or high cholesterol. It aims to see if the drug is safe and effective when taken as part of routine care.
This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
Hear when a new High blood pressure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.